Dyne Therapeutics, Inc. (NASDAQ:DYN) COO Susanna Gatti High Sells 8,976 Shares

Dyne Therapeutics, Inc. (NASDAQ:DYN) COO Susanna Gatti High sold 8,976 shares of the business’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $34.41, for a total value of $308,864.16. Following the completion of the sale, the chief operating officer now owns 131,636 shares of the company’s stock, valued at approximately $4,529,594.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Susanna Gatti High also recently made the following trade(s):

• On Friday, June 21st, Susanna Gatti High sold 29,787 shares of Dyne Therapeutics stock. The shares were sold at an average price of $35.01, for a total value of $1,042,842.87.
• On Monday, June 24th, Susanna Gatti High sold 10,163 shares of Dyne Therapeutics stock. The stock was sold at an average price of $35.33, for a total value of $359,058.79.

Dyne Therapeutics Price Performance

Dyne Therapeutics stock opened at $36.41 on Friday. Dyne Therapeutics, Inc. has a 1-year low of $6.40 and a 1-year high of $47.45. The business has a fifty day moving average price of $41.28 and a 200-day moving average price of $33.47. The stock has a market capitalization of $3.18 billion, a price-to-earnings ratio of -9.17 and a beta of 1.07.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.02. On average, equities research analysts anticipate that Dyne Therapeutics, Inc. will post -2.96 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Algert Global LLC grew its stake in Dyne Therapeutics by 255.1% during the 2nd quarter. Algert Global LLC now owns 97,370 shares of the company’s stock valued at $3,436,000 after purchasing an additional 69,947 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in Dyne Therapeutics by 96.2% in the second quarter. The Manufacturers Life Insurance Company now owns 126,244 shares of the company’s stock valued at $4,455,000 after buying an additional 61,902 shares during the last quarter. AQR Capital Management LLC boosted its position in Dyne Therapeutics by 4.3% in the second quarter. AQR Capital Management LLC now owns 8,495 shares of the company’s stock valued at $300,000 after buying an additional 352 shares during the last quarter. Affinity Asset Advisors LLC acquired a new position in Dyne Therapeutics in the 2nd quarter worth approximately $3,529,000. Finally, First Light Asset Management LLC raised its position in Dyne Therapeutics by 261.0% during the 2nd quarter. First Light Asset Management LLC now owns 382,433 shares of the company’s stock worth $13,496,000 after buying an additional 276,485 shares during the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

Analyst Upgrades and Downgrades

DYN has been the subject of a number of research reports. Oppenheimer reaffirmed an “outperform” rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a research note on Tuesday, September 3rd. Stifel Nicolaus upped their price target on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. Piper Sandler increased their price objective on shares of Dyne Therapeutics from $43.00 to $53.00 and gave the company an “overweight” rating in a research note on Tuesday, August 13th. Guggenheim boosted their price objective on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, August 15th. Finally, StockNews.com cut Dyne Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday. One investment analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Dyne Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $51.40.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.